Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Craig-Hallum 2014 Alpha Select Conference
17 slides from Harrow's conference presentation, Sep 17, 2014
Slide 1: Introduction to Imprimis Pharmaceuticals
INTRODUCTION TO IMPRIMIS PHARMACEUTICALS NASDAQ: IMMY MARK L. BAUM, CEO SEPTEMBER 2014 CRAIG-HALLUM 2014 ALPHA SELECT CONFERENCE
Slide 2: Safe Harbor
imprimis SAFE HARBOR This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlyi
Slide 3: Imprimis
Impomis
Slide 4: Market in Need of a Solution
imprimis MARKET IN NEED OFA SOLUTION OCULAR SURGERY MARKET * Standard of care is self-administered steroid, NSAID and antibiotic eye drop therapy * Significant patient compliance issues; high cost to patients; and increased staff time required for patient counseling * Physicians and patients are dis
Slide 5: Our Novel Solution
OUR NOVEL SOLUTION * Single, simple step during the procedure + >40,000 cases to date 4 (15/1)mgmL Steril Tiamcinolone Acé \loxifloxacin HCl ‘ Superior patent-pending technology allows for an elegant injectable formulation
Slide 6: Imprimis
Imprimis Courtesy of Dr. James Lewis
Slide 7: Ophthalmology Launch
imprimis OPHTHALMOLOGY LAUNCH gs, ~% DROP = GO = [Ess Since Our Go Dropless Launch in April 2014 uw * More than 100 ophthalmologists have been trained or have begun prescribing our formulations for their patients * Atleading eye meetings, physicians report >90% success in eliminating the use of post
Slide 8: Digital Marketing Tools
imprimis DIGITAL MARKETING TOOLS Training Portal Development and Website Relaunch ee eee eens - i a Online training portal provides GoDropless.com gets a new new users with education on look and feel, is optimized for injection technique, special mobile/tablet, and splits into cases, and preparation
Slide 9: Why Go Dropless Campaign
“WHY GO DROPLESS” CAMPAIGN Imprimis SHORT COMPILATION OF 18 VIDEOS ON SITE TRADE PRESS AD 95% of Leading Cataract Surgeons Would Prefer Dropless Therapy” ” =Go 2 PROP Sot SS ee Se WEB BANNER AD — NEWSWIRE TO 20,000 % DROp 95% of Leading Cataract Surgeons : '= LESS Surveyed Would Prefer Dropless Ther
Slide 10: Returning Power to the Prescriber
., RETURNING POWER TO THE Sila 3.Rx PAD 505(b)(2) imprimis %: Single;genenoidrug (C) * Each formulation is patient-specific » Combo of generic drugs (G+G) Time Speed to market Expense Low-cost development Inflexibility Flexibility Food & Drug Cosmetic Act (FDCA) State Pharmacy Law & DQSA (2013)
Slide 11: Imprimis Formulation Pipeline
Imprimis FORMULATION PIPELINE OPHTHAMOLOGY TriMoxi + TriMoxiVanc and Predisone-Moxifloxacin (PredMoxi) Human * Sterile Injection During Ocular Surgery * Combination Eye Drops Post-LASIK Surgery Animal * In Development for Veterinarian Ocular Surgery Compounded Mydriatics * Lyophilized Epinephrine, S
Slide 12: Market & Competitive Analysis
MARKET & COMPETITIVE imprimis ANALYSIS Ophthalmology Competitors: Bausch+Lomb (VRX); Allergan (AGN); Alcon (NVS) 3.6 million cataract surgeries annually in U.S. / 22 million globally US LASIK surgeries: 700,000 / year $1B U.S. drug market (NSAID, steroid and antibiotic) Estimated average eye drop co
Slide 13: Defining Success
Imprimis DEFINING SUCCESS 2014 and 2015 Strategic Goals * Grow ophthalmology division * Continue adoption momentum * Build on novel ophthalmology portfolio ° au pricing with public and private payers by mid- ¢ Monetize non-ophthalmology formulations * Prepare for planned 2015 urology launch * Contin
Slide 14: Imprimis Financial Snapshot
Imprimis FINANCIAL SNAPSHOT Trading Symbol: NASDAQ: IMMY Current Price per Share (9-10-14): $7.94 Market Cap: $70 Million 52-Wk Range: $3.01 - $9.62 Average Daily Trading Volume: 21,000 shares * Clean capital structure No preferred shares or convertible debt; No significant debt Strong cash position
Slide 15: Imprimis Summary
Imprimis SUMMARY * Focused on proprietary sterile and topical drug formulations in the ophthalmology and urology therapeutic areas e Unique business model de-risks pharmaceutical development * Proprietary drug formulations are born from the clinical experience of physician prescribers and pharmacist
Slide 16: Questions?
imprimis QUESTIONS?
Slide 17: Presentation By
imprimis PRESENTATION BY: Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) 12264 El Camino Real, #350 San Diego, CA 92130 Mark Baum Founder, CEO and Board of Directors (858) 704-4042 mark@imprimispharma.com Investor Relations Bonnie Ortega Director of Investor Relations (858) 704-4587 ja@imy harma.com
Imprimis Pharmaceuticals — Craig-Hallum 2014 Alpha Select Conference on 6ix